Loading
Life sciences · Journal article
Human Vaccines & Immunotherapeutics · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The Immunotherapy of Cancer (ITOC) meeting is a leading international conference that unites immuno-oncology researchers and clinicians from around the world to present and discuss emerging research and latest developments in the field. Now in its 12th edition, the conference took place in Munich in March 2026 and spotlighted the remarkable evolution of immunotherapy from an innovative treatment modality with genuine curative potential. The highlight of ITOC12 was the Lifetime Achievement Award presented to Dr. John Haanen in recognition of his pioneering contributions to the clinical development of T‑cell-based therapies. Throughout the meeting, discussions addressed novel advances and modalities but also autoimmune and inflammatory adverse effects, as well as the relevance of financial toxicity as a critical consideration for ensuring sustainable and equitable patient access.